Search Results

Clinical program initiated for B2-adrenergic receptor agonist in status asthmaticus.

• Source: World Disease Weekly. 2006, pages. 1155

Record details

Clinical program initiated for B2-adrenergic receptor agonist in status asthmaticus.

• Source: Health & Medicine Week. 2006, pages. 1154

Record details

MediciNova announces the initiation of a clinical development programme to evaluate MN-221 for the treatment of status asthmaticus.

• Source: Chemical Business Newsbase. 2006.

Record details

Clinical program initiated for B2-adrenergic receptor agonist in status asthmaticus

• Source: Health & Medicine Week. July 10, 2006, p1154.

Record details

RESPIRATORY DISORDERS.

Subjects: TREATMENT of respiratory diseases; PHARMACEUTICAL industryGLAXOSMITHKLINE; NOVARTIS AG; MERCK & Co. Inc.

• Source: MPR - Pharmacists' Edition; Fall2015, Vol. 9 Issue 3, p212-230, 18p, 2 Charts

Record details

Off label use von Notfallmedikamenten im Kindesalter.

• Authors : Erker, C.G.; Möllmann, M.

Subjects: OFF-label use (Drugs); PEDIATRIC emergencies; PEDIATRIC anesthesia

• Source: Anaesthesist; Feb2013, Vol. 62 Issue 2, p130-136, 7p

Record details

Artist® Tablets (Carvedilol) for Hypertensive Patients in Japan.

• Authors : Mori, Yoshihiro; Nishikawa, Yasuhiro; Iizuka, Tomoko

Subjects: ADRENERGIC beta blockers; DRUG marketing; HYPERTENSIONJAPAN

• Source: Drugs in R&D; 2011, Vol. 11 Issue 2, p171-190, 20p, 1 Diagram, 7 Charts, 3 Graphs

Record details

RESPIRATORY DISORDERS.

Subjects: DRUGS; PHARMACEUTICAL industry; EQUIPMENT & suppliesGLAXOSMITHKLINE; ASTRAZENECA PLC; MYLAN Specialty LP

• Source: MPR - Pediatricians' Edition; Spring/Summer2014, Vol. 25 Issue 1, p139-166, 20p

Record details

RESPIRATORY DISORDERS.

Subjects: PHARMACEUTICAL industry; TREATMENT of respiratory diseases; DRUGSGLAXOSMITHKLINE; ASTRAZENECA PLC; SUNOVION Pharmaceuticals Inc.

• Source: MPR - Pediatricians' Edition; Spring/Summer2013, Vol. 24 Issue 1, p141-170, 20p, 8 Charts

Record details

Astrazeneca - TEZSPIRE met both co-primary endpoints in the Phase III WAYPOINT trial in patients with chronic rhinosinusitis with nasal polyps.

• Source: ENP Newswire. November 11, 2024.

Record details